Jade Biosciences (JBIO) Net Cash Flow (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Net Cash Flow data on file, last reported at -$33.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 404.99% year-over-year to -$33.4 million; the trailing twelve-month figure through Mar 2026 stood at -$7.7 million (down 104.69% YoY), and the FY2025 full-year result was $19.1 million, up 85.9% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$33.4 million, down from $38.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $158.2 million in Q2 2025 and bottomed at -$170.8 million in Q3 2025.
• The 5-year median for Net Cash Flow is -$2.9 million (2022), against an average of $6.9 million.
• Peak annual rise in Net Cash Flow reached 5133.72% in 2023, while the deepest fall reached 39395.45% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$22000.0 in 2022, then tumbled by 39395.45% to -$8.7 million in 2023, then surged by 1049.65% to $82.5 million in 2024, then plunged by 53.57% to $38.3 million in 2025, then plunged by 187.09% to -$33.4 million in 2026.
• The last three Net Cash Flow figures came in at -$33.4 million (Q1 2026), $38.3 million (Q4 2025), and -$170.8 million (Q3 2025), per Business Quant data.

Peer Comparison